Clinical activity of agen1181 demonstrated across nine treatment-resistant cancers at sitc

Lexington, mass., nov. 12, 2021 (globe newswire) -- agenus (nasdaq: agen), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the presentation of new clinical data for agen1181 (fc-enhanced anti-ctla-4) as monotherapy and in combination with balstilimab (anti-pd-1) at the society for immunotherapy of cancer (sitc) 36th annual meeting.
AGEN Ratings Summary
AGEN Quant Ranking